Amalgamated Bank Has $5.99 Million Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Amalgamated Bank increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 91,048 shares of the biotechnology company’s stock after purchasing an additional 382 shares during the quarter. Amalgamated Bank’s holdings in BioMarin Pharmaceutical were worth $5,985,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Creative Planning lifted its stake in shares of BioMarin Pharmaceutical by 20.9% in the third quarter. Creative Planning now owns 14,300 shares of the biotechnology company’s stock worth $1,005,000 after buying an additional 2,475 shares during the last quarter. Blue Trust Inc. boosted its holdings in BioMarin Pharmaceutical by 504.9% during the third quarter. Blue Trust Inc. now owns 859 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 717 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at about $12,940,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of BioMarin Pharmaceutical by 16.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,404 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 1,167 shares during the period. Finally, Forsta AP Fonden lifted its position in shares of BioMarin Pharmaceutical by 10.3% during the 3rd quarter. Forsta AP Fonden now owns 36,400 shares of the biotechnology company’s stock worth $2,559,000 after purchasing an additional 3,400 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of BioMarin Pharmaceutical stock in a transaction on Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the completion of the transaction, the chief accounting officer now owns 13,105 shares in the company, valued at approximately $896,119.90. The trade was a 9.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.85% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

BMRN has been the topic of a number of research analyst reports. Canaccord Genuity Group lowered their target price on BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. Wedbush restated an “outperform” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price for the company in a research note on Monday. StockNews.com raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 22nd. Finally, William Blair downgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.00.

BioMarin Pharmaceutical Stock Down 3.3 %

Shares of NASDAQ:BMRN opened at $68.81 on Thursday. The company’s fifty day moving average is $65.11 and its 200-day moving average is $70.47. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. BioMarin Pharmaceutical Inc. has a 52 week low of $60.63 and a 52 week high of $94.85. The company has a market capitalization of $13.11 billion, a PE ratio of 31.28, a P/E/G ratio of 0.61 and a beta of 0.28.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.